Degenerative diseases i.e., diabetes, neurodegenerative diseases, organ failure etc., have emerged as the biggest health problems to our aging world. Applied biotechnologies with an attempt for developing regenerative medicines have gained the fastest growth over the last decade. These essential biotechnologies include the discovery of generating induced pluripotent stem cells from adult somatic cells, the emerging of DNA nucleases (e.g., TALENs, CRISPR/Cas9) mediated targeted genome editing in a wide range of somatic cells and organisms, the development of biologically compatible nanomaterials, the improvement of animal engineering, the advances in preclinical assessment and arising single cell and spatial sequencing technologies. In our group, we focusing on the development, improvement and integration of these biotechnologies for developing better treatments for patients. To achieve this, we establish the Danish Regenerative Engineering Alliance for Medicine (DREAM) team, aiming to create a research and innovation platform, through which we can share our outstanding resources, establish close collaborations, enhance communications, educate future talents, and together we generative regenerative solutions for medical problems. Specifically, we are focusing on (1) Development and improvement of applied genome technologies; (2) Deciphering disease (diabetes complicates and cancers) mechanisms using advanced transcriptomics/genomics technologies and AI; (3) Developing novel and effective treatments for inherited human diseases, i.e., Duchenne Muscular Dystrophy (DMD) through CRISPR gene editing and stem cell technologies; (4) Developing next generation genetically modified pigs for organ transplantation